Switches between biologics in patients with moderate‐to‐severe psoriasis: results from the French cohortPSOBIOTEQ
Journal of the European Academy of Dermatology and Venereology2022Vol. 36(11), pp. 2101–2112
Citations Over TimeTop 11% of 2022 papers
R. Curmin, S. Guillo, Yann De Rycke, H. Bachelez, M. Beylot‐Barry, N. Bénéton, O. Chosidow, A. Dupuy, P. Joly, D. Jullien, M‐A Richard, M. Viguier, É. Sbidian, C. Paul, E. Mahé, Florence Tubach, the PSOBIOTEQ Study Group
Abstract
This study described the switching patterns of biologic treatments and showed how they changed over time, due to the availability of the new biologic agents primarily IL-17 inhibitors.
Related Papers
- → Medication adherence and persistence in the treatment of rheumatoid arthritis with adalimumab and etanercept. Six years of analysis(2014)9 cited
- → Dynamics of serum levels of TNF-α in a longitudinal follow-up study in 98 patients with juvenile idiopathic arthritis treated with anti-TNF-α biological drugs(2024)5 cited
- → Paradoxical worsening of psoriasis when switching from etanercept to adalimumab: A case series(2010)18 cited
- → PSS24 Cost-Effectiveness of Ustekinumab vs Etanercept for Severe Psoriasis(2011)1 cited
- → Su1875 – Development of Targeted Therapeutic Antibodies for the Treatment of Inflammatory Bowel Disease(2019)